Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104564 | 0.94 | PTGS2 (0.57) | PTGS2PTGS1MAPTTP53 | |
| SCHEMBL5109297 | 0.90 | PTGS2 (0.69) | PTGS2PTGS1MAPTTP53 | |
| SCHEMBL5109194 | 0.89 | PTGS2 (0.59) | PTGS2PTGS1MAPTTP53MEN1 | |
| SCHEMBL5116650 | 0.86 | PTGS2 (0.62) | PTGS2PTGS1KMT2A | |
| SCHEMBL5114318 | 0.84 | PTGS2 (0.72) | PTGS2PTGS1MAPT | |
| SCHEMBL5109317 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1MAPTTP53MEN1 | |
| SCHEMBL5107379 | 0.83 | PTGS2 (0.61) | PTGS2PTGS1 | |
| SCHEMBL5114300 | 0.81 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL5115108 | 0.80 | PTGS2 (0.74) | PTGS2PTGS1 | |
| SCHEMBL5107441 | 0.80 | PTGS2 (0.61) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410994-B2 | Indole derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060178420-A1 | Indole derivatives as anti-inflammatory agents | BROKA CHRIS A | 2006-08-10 | — | — | US | disclosed |
| US-7074939-B2 | Indole derivatives as anti-inflammatory agents | ROCHE PALO ALTO LLC (US) | 2006-07-11 | — | — | US | disclosed |
| US-20050176803-A1 | Indole derivatives as anti-inflammatory agents | BROKA CHRIS A (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1438289-B1 | INDOLE DERIVATIVES AS COX II INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-6872744-B2 | Indole derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1438289-A1 | INDOLE DERIVATIVES AS COX II INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2004-07-21 | — | — | EP | disclosed |
| US-20030130337-A1 | Indole derivatives as anti-inflammatory agents | SYNTEX (U.S.A.) LLC | 2003-07-10 | — | — | US | disclosed |
| WO-2003029212-A1 | INDOLE DERIVATIVES AS COX II INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130337-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 4/4885PTGS1 3/4885MAPT 2905/4885 |
| US-20050176803-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 5/4885PTGS1 3/4885MAPT 2199/4885 |
| US-20060178420-A1 | Indole derivatives as anti-inflammatory agents | IDO1, IDO2, PTGS1 | PTGS2 5/4885PTGS1 3/4885MAPT 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.